Anti-Marinobufagenin Antibodies and Uses Thereof
AssigneeCTS Biopharma LLC
InventorsJames W. Larrick, John M. Wages, Andrew R. Mendelsohn, Vikram Sharma, Bo Yu
Life of this patent
Estimating the term…
Abstract
The present disclosure provides chimeric, humanized and human monoclonal antibodies (mAbs) and fragments thereof that specifically bind to marinobufagenin (MBG) with high affinity. The anti-MBG mAbs and fragments thereof can be used to treat MBG-associated disorders, including hypertensive disorders and fibrotic disorders, optionally in combination with an additional therapeutic agent. Furthermore, the anti-MBG mAbs and fragments thereof can be used for diagnostic purposes, including to detect MBG in biological samples and to diagnose MBG-associated disorders.
Claims41
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating a subject, comprising the steps of:
- providing a subject wherein the subject has an MBG-associated disorder that has an elevated level of marinobufagenin, administering to the subject an anti-marinobufagenin antibody, wherein the anti-marinobufagenin antibody binds a marinobufagenin in the subject, whereby the MBG-associated disorder is treated.
Dependencies are inferred from the claim text.